secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001140361-23-009748
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst sells rare bleeding disorder assets to GC Biopharma for $6M; GNI revenue $102M
--------------------------------------------------------------------------------

- Sold MarzAA, DalcA, and CB-2679d-GT to GC Biopharma for $6M total ($1M upfront, $5M holdback due Feb 2025).
- Net proceeds from sale to be distributed to holders of contingent value rights issued to stockholders of record Jan 5, 2023.
- GNI Group reported FY2022 revenue ~$102M and net profit ~$23M from pirfenidone sales in China for IPF.
- GNI Transactions (purchase of F351 assets and controlling interest in Beijing Continent) remain pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/0001140361-23-009748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/brhc10049211_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-009748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer